2008
DOI: 10.1504/tbj.2008.026477
|View full text |Cite
|
Sign up to set email alerts
|

Expression, purification and comparative characterisation of enzymatically deactivated recombinant botulinum neurotoxin type A

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2013
2013
2018
2018

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 18 publications
(12 citation statements)
references
References 32 publications
0
12
0
Order By: Relevance
“…Recombinant BoNT/A LC and DR BoNT/A were isolated and purified from Escherichia coli transformed with pBN3 vectors harboring BoNT/A LC and the double mutant DR BoNT/A genes respectively, as described previously [25,26]. BoNT/A, recombinant BoNT/ B & E LC were provided by BB Tech (North Dartmouth, MA).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Recombinant BoNT/A LC and DR BoNT/A were isolated and purified from Escherichia coli transformed with pBN3 vectors harboring BoNT/A LC and the double mutant DR BoNT/A genes respectively, as described previously [25,26]. BoNT/A, recombinant BoNT/ B & E LC were provided by BB Tech (North Dartmouth, MA).…”
Section: Methodsmentioning
confidence: 99%
“…DR BoNT/A is the recombinant BoNT/A with two mutations on the enzymatic site of light chain (E224A/E262A). This detoxified protein has been confirmed to have identical structure and biological functions (binding, internalization and translocation on neuronal cells) to its wild type toxin, with much reduced endopeptidase activity [25]. Due to the absence of endopeptidase activity, the toxicity of DR BONT/A is approximately 100,000 fold less than that of native toxin, therefore providing an excellent surrogate to study BoNT without sophisticated laboratory requirements for tier one select agents.…”
Section: Introductionmentioning
confidence: 99%
“…However, both methods involve the use of C. botulinum culture which require regulatory issues, including a facility to address biosafety concerns. As an alternative approach, we have utilized a PCR amplified DNA fragment encoding LC-TD/A region from the DrBoNT/A clone, which is a non-toxic variant of BoNT/A, previously produced in our lab [17]. The method described in the current paper involves use of heterologous expression E.coli system for production of rLC-TD/A protein which resulted in 2 to 20-fold higher yield (1.5 mg per gm cell paste or 1.5 mg per liter of E.coli culture) with > 95 % purity as compared to the methods published (20 fold higher than that reported by [15], and 2 fold higher than that by [16], respectively).…”
Section: Discussionmentioning
confidence: 99%
“…The DNA fragment for rLC-TD/A was obtained from deactivated recombinant BoNT/A (DrBoNT/A) vector clone [17] that is exempted by CDC from the select agent regulations. DrBoNT/A clone produces catalytically inactive protein consisting of two glutamic acid mutations (E224 and E262) to alanine at the active site of BoNT/A LC which has been demonstrated by in vitro SNAPtide® [17] and mouse neuromuscular junction assay [18].…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation